backgroundpurpos
nonalcohol
fatti
liver
diseas
nafld
common
chronic
liver
diseas
rang
sever
steatosi
cirrhosi
type
diabet
mellitu
caus
primari
nafld
thiazolidinedion
shown
enhanc
insulin
sensit
improv
glycem
control
type
diabet
patient
improv
histolog
marker
nonalcohol
steatohepat
studi
aim
determin
safeti
effect
rosiglitazon
inadequ
control
type
diabet
patient
nafld
method
taiwanes
type
diabet
patient
inadequ
control
insulin
secretagogu
metformin
histori
signific
alcohol
ingest
mildli
elev
serum
aspart
aminoy
transferas
ast
andor
alanin
aminotransferas
alt
diagnosi
fatti
liver
determin
ultrasonographi
enrol
patient
treat
week
rosiglitazon
mg
daili
primari
endpoint
chang
ast
alt
level
baselin
reduct
result
total
patient
complet
studi
treatment
without
seriou
advers
event
treatment
two
patient
discontinu
due
elev
ast
alt
level
three
time
upper
limit
normal
noncompli
loss
followup
six
patient
patient
complet
studi
treatment
mean
fast
plasma
glucos
fast
plasma
insulin
mean
alt
homeostasi
model
assess
insulin
resist
significantli
reduc
normal
ast
alt
level
achiev
maintain
least
three
consecut
measur
end
studi
period
patient
weight
increas
mean
kg
p
conclus
rosiglitazon
reason
well
toler
patient
inadequ
control
type
diabet
nafld
onethird
patient
show
improv
liver
function
treatment
j
formo
med
assoc
nonalcohol
fatti
liver
diseas
nafld
common
often
subtl
chronic
liver
diseas
rang
steatosi
alon
steatosi
inflamm
necrosi
fibrosi
cirrhosi
recent
data
indic
nafld
repres
common
form
liver
disord
also
frequent
caus
chronic
liver
diseas
nafld
character
asymptomat
mildli
elev
serum
aminotransferas
level
r
absenc
signific
alcohol
intak
chronic
liver
diseas
primari
nafld
caus
condit
associ
insulin
resist
syndrom
type
diabet
obes
hyperlipidemia
sever
type
nafld
nonalcohol
steatohepat
nash
lead
progress
fibrosi
eventu
cirrhosi
therapi
demonstr
effect
nafld
focu
manag
modifi
potenti
risk
factor
obes
hyperlipidemia
poor
diabet
control
thiazolidinedion
tzd
shown
enhanc
insulin
sensit
peripher
organ
liver
therebi
result
improv
glycem
control
patient
type
diabet
addit
treatment
nash
w
rosiglitazon
improv
insulin
sensit
histolog
marker
nash
rosiglitazon
may
also
directli
favour
influenc
necroinflammatori
chang
fibrogenesi
result
downregul
inflammatori
cascad
fibrosi
benefit
therefor
rais
potenti
success
treat
type
diabet
patient
nafld
tzd
troglitazon
first
tzd
found
improv
hepat
histolog
patient
nash
side
effect
hepatotox
led
subsequ
withdraw
market
two
newer
tzd
rosiglitazon
pioglitazon
demonstr
high
incid
hepatotox
seen
troglitazon
accumul
exposur
rosiglitazon
pioglitazon
clinic
trial
postmarket
experi
continu
littl
evid
druginduc
hepatotox
newer
tzd
also
report
improv
biochem
histolog
featur
nash
support
role
insulin
resist
pathogenesi
diseas
howev
sinc
subject
studi
mostli
nondiabet
patient
sinc
studi
popul
small
efficaci
safeti
tzd
poorli
control
diabet
patient
nafld
remain
unclear
knowledg
safeti
rosiglitazon
effect
glucos
liver
function
poorli
control
type
diabet
nafld
previous
evalu
primari
aim
studi
determin
safeti
rosiglitazon
use
inadequ
control
type
diabet
patient
nafld
w
alreadi
treat
toler
maxim
dose
insulin
secretagogu
metformin
secondari
aim
studi
c
evalu
glycem
nonglycem
metabol
effect
includ
chang
liver
function
patient
studi
conduct
mackay
memori
hospit
taipei
taiwan
februari
june
sixtyeight
taiwanes
patient
inadequ
control
type
diabet
toler
maximum
stabl
regimen
insulin
secretagogu
glibenclamid
mgday
gliclazid
mgday
glimepirid
mgday
repaglinid
mgday
metformin
mgday
least
month
studi
period
enrol
r
inclus
criteria
age
year
older
glycosyl
hemoglobin
histori
alcohol
intak
absenc
signific
alcohol
ingest
gweek
mildli
elev
level
time
upper
limit
normal
rang
uln
serum
aspart
aminotransferas
ast
ul
refer
rang
ul
andor
alanin
aminotransferas
alt
ul
refer
rang
ul
record
least
three
time
within
year
studi
alt
level
higher
ast
level
neg
diagnost
test
viral
hepat
b
c
bodi
mass
index
bmi
kgm
fatti
liver
determin
abdomin
ultrasonographi
present
diffus
increas
bright
echogen
exclus
criteria
includ
follow
curr
rent
previou
treatment
rosiglitazon
tzd
pregnanc
lactat
clinic
evid
activ
liver
diseas
normal
time
uln
level
ast
andor
alt
secondari
caus
fatti
liver
gastrointestin
bypass
surgeri
medic
induc
c
steatosi
one
episod
hypoglycem
unawar
clinic
signific
heart
failur
nyha
fc
iii
peripher
edema
throughout
cours
studi
patient
w
instruct
continu
lifestyl
includ
diet
exercis
maintain
studi
entri
patient
allow
continu
use
antihypertens
lipidlow
agent
take
stabl
dose
least
week
studi
entri
entir
studi
studi
protocol
requir
patient
maintain
respect
dose
agent
level
studi
entri
prospect
openlabel
studi
consist
screen
period
follow
treatment
w
rosiglitazon
period
last
least
w
week
enrol
patient
underw
comprehens
medic
histori
physic
examin
patient
gave
written
inform
consent
studi
particip
laboratori
measur
includ
fast
plasma
glucos
fpg
ast
alt
baselin
week
treatment
fast
plasma
insulin
total
cholesterol
tc
triglycerid
tg
hdlcholesterol
hdlc
ldlcholesterol
ldlc
baselin
week
treatment
dyslipidemia
defin
tc
mgdl
andor
tg
mgdl
postprandi
glucos
insulin
level
measur
baselin
week
treatment
bodi
composit
analysi
perform
baselin
week
treatment
bodi
weight
measur
nearest
kg
baselin
interv
patient
w
start
mg
daili
dose
rosiglitazon
titrat
mgday
interv
level
remain
studi
protocol
requir
dose
adjust
made
oral
hypoglycem
antihypertens
andor
lipidlow
agent
rosiglitazon
treatment
respons
group
defin
patient
w
achiev
normal
ast
alt
level
followup
continu
maintain
normal
ast
alt
level
least
three
consecut
assess
end
studi
period
safeti
paramet
assess
clinic
visit
therapi
patient
develop
ast
andor
alt
uln
signific
weight
gain
unaccept
patient
c
seriou
advers
effect
includ
heart
hepat
failur
episod
sever
hypoglycemia
withdrawn
studi
sever
hypog
glycemia
defin
hypoglycemia
requir
hospit
assist
anoth
person
treat
andor
blood
glucos
mgdl
followup
abdomin
sonographi
perform
month
rosiglitazon
use
plasma
glucos
level
determin
hexokinas
enzymat
method
insulin
level
coatacount
radioimmunoassay
procedur
diagnost
product
corpor
la
usa
highperform
boron
affin
liquid
chromatographi
method
primu
tm
system
mo
usa
normal
rang
ast
alt
determin
tri
buffer
without
method
peroxidas
method
use
tc
determin
lipas
method
tg
direct
immunoinhibit
method
hdlc
ldlc
measur
triblock
copolym
c
acyclodextrin
sulfat
method
enzymat
colorimetr
method
use
hitachi
automat
analyz
tokyo
japan
homeostasi
model
assess
insulin
resist
homair
calcul
fast
plasma
insulin
fpg
measur
accord
formula
homair
fast
plasma
insulin
ml
fast
plasma
glucos
mmoll
blood
pressur
measur
commenc
month
start
rosiglitazon
treatment
waist
circumfer
wc
measur
midway
iliac
crest
lowest
rib
end
expir
bodi
composit
measur
use
eightpoint
tactil
electrod
multifrequ
segment
bioelectr
imped
analyz
inbodi
f
biospac
co
ltd
seoul
korea
hour
fast
accord
manufactur
instruct
measur
taken
baselin
week
treatment
descript
statist
use
summar
demograph
biochem
characterist
baselin
week
rosiglitazon
treatment
pair
student
test
use
compar
chang
paramet
baselin
treatment
onew
way
analysi
varianc
anova
fisher
exact
test
use
assess
chang
time
chang
percentag
case
normal
ast
alt
time
stepwis
regress
analysi
perform
use
spss
version
spss
inc
chicago
il
usa
evalu
relationship
alt
homair
bodi
w
weight
fat
mass
simpl
linear
correl
use
evalu
relationship
chang
weight
weight
fat
mass
alt
homair
alt
p
valu
consid
statist
signific
patient
complet
studi
treatment
eight
discontinu
treatment
reason
withdraw
discontinu
treatment
follow
elev
ast
alt
level
uln
two
patient
day
respect
peak
ast
alt
valu
ast
alt
respect
noncompli
loss
followup
six
patient
day
respect
six
patient
noncompli
loss
followup
four
return
outpati
clinic
variou
period
time
sever
acut
respiratori
syndrom
outbreak
taiwan
loss
followup
two
patient
six
patient
exclud
analys
end
studi
mean
dose
rosiglitazon
remain
patient
mgday
take
mgday
clinic
biochem
characterist
patient
baselin
week
rosiglitazon
treatment
shown
tabl
rosiglitazon
treatment
decreas
mean
fpg
mgdl
p
p
fast
plasma
insulin
l
uml
p
postprandi
glucos
mgdl
p
homair
p
mean
reduc
significantli
baselin
patient
mean
alt
decreas
significantli
ul
ul
p
ast
decreas
ul
ul
although
chang
signific
p
mean
tc
ldlc
hdlc
increas
significantli
respect
p
tg
decreas
although
reduct
signific
p
mean
diastol
blood
pressur
show
signific
reduct
end
treatment
period
mmhg
mmhg
p
mean
systol
blood
pressur
show
signific
chang
weight
increas
pat
tient
treatment
period
mean
weight
increas
kg
p
although
incid
mild
moder
clinic
edema
sever
enough
requir
discontinu
treatment
patient
signific
increas
mean
fat
mass
kg
p
f
percentag
bodi
fat
p
bmi
kgm
p
f
howev
weight
total
bodi
water
chang
significantli
mean
wc
decreas
cm
p
mean
waisthip
ratio
whr
reduc
p
mean
level
time
perr
centag
patient
normal
liver
function
respons
group
time
shown
figur
mean
decreas
rapidli
first
week
treatment
p
slower
coni
tinu
decreas
end
studi
period
addit
rosiglitazon
patient
dyslipidemia
w
dyslipidemia
end
studi
p
respons
group
normal
liver
function
first
note
earli
th
week
start
rosiglitazon
patient
incid
increas
th
week
th
week
c
signific
differ
metabol
figur
f
h
l
f
percentag
case
normal
liver
function
mean
time
studi
group
n
oneway
analysi
varianc
use
mean
time
test
use
percentag
case
normal
aspart
aminotransferas
ast
alanin
aminotransferas
alt
time
p
p
paramet
fpg
postprandi
glucos
homair
tc
tg
hdlc
ldlc
alt
ast
baselin
respons
nonrespons
group
stepwis
regress
analysi
show
signific
correl
alt
alt
homair
alt
bodi
weight
well
alt
fat
mass
linear
regress
analysi
show
signific
correl
chang
weight
p
chang
weight
fat
mass
p
figur
followup
abdomin
sonographi
rosiglitazon
treatment
show
signific
chang
fatti
liver
statu
either
respons
nonrespons
group
initi
patient
two
patient
withdrew
due
elev
ast
alt
uln
one
two
patient
withdrew
due
elev
liver
transaminas
level
followup
discontinu
rosiglitazon
show
ast
alt
level
reduc
uln
patient
ast
alt
level
fluctuat
stop
rosiglitazon
remain
uln
patient
otherwis
stabl
patient
develop
episod
hypoglycemia
heart
failur
weight
gain
side
effect
sever
enough
necessit
withdraw
treatment
protocol
initi
patient
complet
entir
cours
rosiglitazon
treatment
two
patient
withdrew
studi
due
elev
ast
alt
g
uln
exclud
six
patient
loss
followup
noncompli
patient
complet
treatment
cours
seriou
advers
event
although
mean
bodi
weight
sigt
nificantli
increas
result
suggest
rosiglitazon
safe
use
inadequ
control
type
diabet
patient
nafld
mildli
elev
liver
enzym
studi
addit
rosiglitazon
establish
regimen
insulin
secretagogu
g
metformin
effect
lower
fpg
patient
inadequ
control
type
diabet
addit
rosiglitazon
result
reduct
mean
p
r
decreas
homair
tabl
greater
decreas
report
previou
studi
end
treatment
period
respons
group
compris
patient
normal
liver
function
first
note
patient
earli
month
start
treatment
pathogenesi
nafld
clearli
establish
prevail
theori
two
hit
hypothesi
propos
day
jame
first
hit
attribut
accumul
fat
within
liver
second
hit
attribut
oxid
stress
initi
fibrosi
via
proinflammatori
cytokin
sever
studi
demonstr
insulin
resist
associ
nafld
sever
insulin
resist
tend
increas
stage
nafld
improv
liver
function
found
previou
trial
pioglitazon
treatment
patient
type
diabet
addit
incid
elev
ast
alt
uln
low
previou
trial
tzd
monotherapi
combin
therapi
studi
tzd
report
improv
biochem
histolog
featur
nash
nondiabet
patient
prospect
pilot
studi
nondiabet
patient
biopsyproven
nash
treat
pioglitazon
week
end
week
serum
alt
decreas
normal
patient
hepat
fat
content
size
determin
magnet
reson
imag
mri
also
decreas
use
strict
criteria
histolog
improv
occur
twothird
patient
w
strong
posit
correl
chang
fat
liver
determin
mri
degre
steatosi
determin
liver
biopsi
anoth
studi
adult
biopsyproven
nash
w
treat
rosiglitazon
week
patient
complet
treatment
significantli
improv
insulin
sensit
mean
serum
alt
level
iul
initi
iul
end
treatment
mean
global
necroinflammatori
score
significantli
improv
treatment
biopsi
patient
r
longer
met
report
criteria
nash
treatment
result
indic
treatment
tzd
lead
improv
biochem
histolog
featur
nash
support
role
insulin
resist
pathogenesi
diseas
r
patient
inadequ
control
type
diar
bete
nafld
mildli
abnorm
liver
function
result
studi
suggest
trial
rosiglitazon
improv
liver
function
within
month
onethird
patient
r
patient
requir
longterm
followup
monitor
blood
glucos
control
liver
function
nafld
chang
insulin
sensit
present
studi
suggest
rosiglitazon
safe
benefici
effect
liver
function
poorli
control
type
diabet
patient
nafld
improv
liver
function
may
result
sever
factor
first
tzd
improv
insulin
resist
increas
insulin
sensit
peripher
organ
liver
second
tzd
improv
sever
compon
metabol
syndrom
could
benefici
affect
endotheli
function
includ
reduct
circul
concentr
free
fatti
acid
improv
lipid
profil
third
tzd
import
antig
inflammatori
effect
involv
decreas
adipocytokin
level
eg
reflect
reduc
highsensit
creactiv
protein
level
increas
adiponectin
level
attenu
monocyt
chemoattract
tzd
shown
decreas
inflammatori
marker
much
earlier
fall
either
insulin
glucos
concentr
diabet
studi
confirm
find
r
fairli
rapid
initi
improv
liver
function
observ
much
earlier
fall
glucos
concentr
decreas
associ
chang
alt
associar
tion
found
chang
homair
alt
shown
figur
find
suggest
rosiglitazon
may
effect
beyond
glucos
lower
antiinflammatori
eft
fect
respons
improv
liver
function
signific
chang
fatti
liver
rosiglitazon
use
determin
abdomin
sonographi
either
respond
nonrespond
could
due
rel
short
durat
treatment
biochem
chang
preced
imag
alter
lack
signific
correl
homair
alt
may
due
small
decreas
alt
andor
rel
short
treatment
period
mean
bodi
weight
increas
kg
treatment
period
mainli
attribut
increas
mean
fat
mass
kg
incid
peripher
edema
w
higher
report
tzd
monotherapi
therapi
sulfonylurea
metformin
howev
wc
whr
significantli
decreas
rosiglitazon
use
tabl
indic
peripher
redistribut
fat
previou
report
also
indic
weight
gain
use
drug
tend
peripher
fat
rather
viscer
fat
therefor
may
associ
increas
risk
link
metabol
syndrom
similar
find
studi
rosiglitazon
treatment
result
increas
mean
tc
ldlc
hdlc
decreas
tg
studi
although
chang
signific
mean
diastol
blood
pressur
decreas
significantli
rosiglitazon
use
insulin
resist
hyperinsulinemia
shown
causal
relat
hypertens
direct
effect
vascular
tone
stimul
adrenerg
nervou
system
antinatriuresi
studi
homair
improv
rosiglitazon
use
reduct
diastol
pressur
could
due
improv
insulin
sensit
diagnosi
nafld
base
noninvas
invas
test
liver
biopsi
definit
modal
major
limit
studi
lack
confirm
nafld
liver
biopsi
although
confirm
would
practic
clinic
set
clinic
practic
steatosi
commonli
detect
noninvas
imag
ultrasonographi
comput
axial
tomographi
ct
mri
among
imag
method
sonographi
least
expens
mri
expens
ct
use
diagnosi
nafld
diagnost
accuraci
timedepend
protocolspecif
consider
individu
variabl
well
intraindividu
variabl
r
multipl
examin
absolut
liver
attenu
number
r
argument
liver
f
biopsi
includ
gener
good
prognosi
patient
nafld
lack
establish
effect
therapi
risk
cost
associ
biopsi
clinic
practic
c
diagnosi
nafld
base
ultrasonograph
r
evid
bright
liver
reduc
posterior
attenu
subject
moder
alcohol
consumpt
select
imag
studi
g
liver
biopsi
advantag
avoid
risk
associ
invas
procedur
ultrasonographi
defin
increas
echogen
nafld
thought
reason
sensit
studi
treatment
durat
week
studi
rel
short
longterm
studi
combin
assess
inflammatori
marker
ct
mri
liver
biopsi
need
determin
whether
improv
liver
function
due
improv
fatti
liver
extent
sustain
prolong
period
conclus
studi
found
rosiglitazon
reason
well
toler
reduc
fpg
postprandi
glucos
level
improv
insulin
sensit
patient
inadequ
control
type
diabet
complic
nafld
mildli
elev
transaminas
level
onethird
patient
also
show
improv
liver
function
find
studi
suggest
rosiglitazon
treatment
may
appropri
care
select
patient
monthli
monitor
liver
function
